Tag: medical marijuana

Medical Marijuana Leads To ‘Improvements In Physical, Social, Emotional And Pain-Related’ Quality Of Life, Study Shows

A new study finds that patients who used medical marijuana for three months improved on a variety of health-related quality of life (HRQoL) measures, including physical functioning, bodily pain, social functioning, fatigue and general health.

“Gains were observed in all HRQoL domains assessed after three months of medical marijuana use,” note authors from the Philadelphia College of Osteopathic Medicine and the Public Health Management Corporation, also in Philadelphia. In several measures, however—including physical functioning and pain—patients’ age played a significant role, “with older participants displaying less improvement than younger participants.”

The longitudinal study, published in the Journal of Cannabis Research last week, followed 438 new medical cannabis patients who completed “semi-structured interviews” both before they began using cannabis and again three months into use. Most participants were recommended marijuana to treat either anxiety disorders (61.9 percent) or pain (53.6 percent).

“New medical marijuana users experienced improvements across all domains of HRQoL over the first three months of medical marijuana use for any of the more than 20 qualifying medical conditions for use in” Pennsylvania, the authors wrote. “Notably, participants endorsed greater than 20 percent increases in ratings of their role limitations due to physical health problems and emotional problems, and in social functioning after three months of medical marijuana use.”

Researchers described the study as “one of the largest longitudinal studies of quality of life in individuals using medical marijuana in the US.”

Keep reading

Medical Marijuana Has ‘Promising Results’ For Fibromyalgia Patients, New Study Shows

Marijuana is useful in treating pain and other symptoms related to fibromyalgia, a new study shows—with authors reporting pain relief, improved sleep and better quality of life in patients who vaporized THC-rich cannabis.

Researchers behind the new case series concluded that “cannabinoids treatment showed promising results in the management of chronic pain and other FM [fibromyalgia]-associated symptoms, improving the quality of life of these patients,” though they acknowledged the need for further study given the limited nature of their initial observations.

The research, published in the Journal of Alternative Complementary and Integrative Medicine, looks at the impact of cannabis treatment on three patients in Portugal who used an 18-percent THC cannabis flower product. The product, from the Canadian producer Tilray, is “the only commercially available medical cannabis product in Portugal,” the study notes.

In addition to reductions in pain and improvements in sleep quality—seen in all three subjects—two of the patients also reported decreases in other medication they were seeing, suggesting a substitution effect.

Keep reading

Medical Marijuana Helps People With Arthritis And Other Rheumatic Conditions Reduce Use Of Opioids And Other Medications, Study Shows

New research on the use of medical marijuana among people with rheumatic conditions such as arthritis finds that more than 6 in 10 patients who used medical cannabis reported substituting it for other medications, including NSAIDs, opioids, sleep aids and muscle relaxants. Most patients further said that the use of marijuana allowed them to reduce or stop using those medications entirely.

“The primary reasons for substitution were fewer adverse effects, better symptom management, and concerns about withdrawal symptoms,” says the study, published this month by the American College of Rheumatology. “Substitution was associated with THC use and significantly higher symptom improvements (including pain, sleep, anxiety, and joint stiffness) than nonsubstitution.”

The findings, say authors at the University of Michigan Medical School, McGill University and the University of Buffalo, “suggest that an appreciable number of people with rheumatic diseases substitute medications with [medical cannabis] for symptom management.”

Data for the study came from an online, anonymous survey of adult residents of the United States and Canada, which was advertised on social media and through email contact lists of the Arthritis Foundation and Arthritis Society Canada. Of 1,727 completed surveys, 763 respondents said they currently used cannabis, while 655 said they’d never used marijuana and 268 said they’d used but since discontinued. Researchers analyzed responses of only those who said they were current cannabis users.

“Among 763 participants, 62.5% reported substituting MC products for medications, including nonsteroidal anti-inflammatory drugs (54.7%), opioids (48.6%), sleep aids (29.6%), and muscle relaxants (25.2%),” the report says.

Keep reading

Colombia’s Diverse Environments Grow Marijuana With ‘Uncommon Terpenes’ That Can Have ‘Unique Therapeutic Benefits,’ Study Shows

New research on Colombian-grown cannabis reveals “significant phytochemical diversity” in the plants, uncovering what authors say are “four distinct chemotypes based on cannabinoid profile” as well as plants that are rich in uncommon terpenes.

The findings “underscore Colombia’s capacity to pioneer global C. sativa production,” the study says, “particularly in South America with new emerging markets.”

The diversity in compounds produced by Colombian cannabis plants could benefit not only growers—for example, by increasing resistance to pests and other pathogens—but also the development of unique medical marijuana products, says the study, published in the journal Phytochemical Analysis.

One factor behind the observed biological diversity could be Colombia’s varied environmental zones, the research says. The country is home to snow-covered volcanoes, tropical beaches, deserts, grasslands, rainforest and more. That variety also contributes to Colombia’s other agricultural industries, such as coffee.

Authors of the new study, from universities in Columbia, Germany and the United States, sought out licensed cultivators of medical marijuana across Colombia. Ultimately, growers donated 156 samples from 17 total cultivation sites, representing seven provinces and five different regions.

Keep reading

New Hampshire Governor Signs Bill Allowing Medical Marijuana For Any Condition A Doctor Thinks It Can Help

New Hampshire Gov. Chris Sununu (R) has signed into a law a major medical marijuana expansion bill that will allow doctors to recommend cannabis for any debilitating condition they believe it would improve. Previously, patients needed to be diagnosed with certain specific conditions to qualify for legal marijuana access.

“This is BIG,” Rep. Wendy Thomas (D), sponsor of the newly signed HB 1278, said in an email to Marijuana Moment. “It opens up the therapeutic program to ANY person who has a debilitating or terminal illness.”

Thomas, a cancer survivor and medical marijuana patient herself, told colleagues at a committee hearing earlier this year that cannabis has helped her manage chronic pain, insomnia, eating issues, gastrointestinal issues, PTSD and anxiety. “I found relief from all of these symptoms,” she said, “some of which are not covered in the program.”

The new law adds to the state’s qualifying conditions for medical marijuana “any debilitating or terminal medical condition or symptom for which the potential benefits of using therapeutic cannabis would, in the provider’s clinical opinion, likely outweigh the potential health risks for the patient.”

The provision does not replace New Hampshire’s enumerated list of qualifying conditions, which Thomas has previously described as a useful way for clinicians who are less familiar with cannabis to navigate the system. “The point of this is that they would be allowed to…refer a patient to the program for any condition that they think would fit and benefit the patient,” she told Marijuana Moment earlier this year.

“This bill sets up two paths for health providers,” Thomas said at the time. “For those who are not familiar with cannabis, they can use the legislated symptom and conditions list. For those providers who are cannabis literate, they will be able to recommend the program for a health condition that they think cannabis may be able to help, but that might not be on the list.”

Other examples of symptoms that could be effectively managed with marijuana that are not specifically listed as qualifying conditions, Thomas said, include severe menstrual cramps, symptoms of long COVID and pre-dentist anxiety and post-surgical pain control.

Keep reading

A Fetus Doesn’t Need Its Own Medical Marijuana License, Oklahoma Court Says

Oklahoma resident Amanda Aguilar was arrested after using marijuana while pregnant. Though Aguilar had a medical marijuana prescription, prosecutors reasoned that her fetus did not. They charged the mother of five with child neglect, a felony.

Now, the state’s highest criminal court says prosecutors had no basis to do that.

The ruling should be good news for women who use marijuana to help with morning sickness and other pregnancy ailments. But the opinions in this case make clear that some Oklahoma judges would like to see pregnant marijuana users criminalized.

“The baby has no medical marijuana license,” wrote Judge Gary L. Lumpkin in a dissenting opinion.

Even Judge Scott Rowland, who wrote the majority’s opinion, stressed that the court does not “condone marijuana use by an expectant mother” and urged Oklahoma lawmakers “to consider an addition to the law making clear when, if ever, the licensed use of marijuana may constitute child neglect.”

Keep reading

Ohio Marijuana Officials Send Guidance To Dispensaries On Rules For Opening Day Sales Events, Advertising And More Ahead Of Market Launch

As Ohio moves closer to launching its adult-use marijuana market, regulators have distributed supplemental guidance on the rules for opening day events, advertising and more.

The Division of Cannabis Control (DCC) has been issuing the state’s first dual certificates of operation for marijuana growers, processors and testing labs in recent weeks so they can begin working with both medical and recreational cannabis. Numerous existing retail dispensaries have been granted provisional licenses as well, but so far none of them have been certified to begin operations

Things are moving forward, however, as regulators have commenced inspections of certain marijuana dispensaries to ensure they’re meeting updated compliance requirements as one of the final steps before they’re able to open shop. And in anticipation of those first openings, DCC sent applicants new guidance materials to “prepare for dual-use operations.”

One way that the division is preparing prospective dual licensees is by reminding them of what they can and can’t do to mark their opening day. For example, businesses cannot allow on-site consumption, offer samples (infused or non-infused), have music or food trucks outside the shop, promote the opening with celebratory decor on the exterior or hold a ribbon cutting ceremony outside.

However, they are permitted to have music inside as long as it’s not a live performance. They can also offer complimentary non-alcoholic beverages and promote the opening by holding a ribbon cutting ceremony inside the dispensary.

DCC also advised applicants that, until new advertising rules are enacted, all businesses must still adhere to the existing regulations in place under the state’s medical marijuana law. To help dual licensees, the division provided a template for what they can post without requiring independent approval.

Advertising material for dual licensees may include the opening date, approved dispensary name, dispensary logo, a note about adults 21 years being allowed to access the shop, location and hours of operation, the business website and social media handles and information about whether online orders, drive-thru services and curbside pickup are available.

Keep reading

NFL Moves To Dismiss Player’s Lawsuit Over Penalties For Cannabis Medication Use, Saying THC Can Cause Injuries And ‘Alienation’ Of Fans

The NFL and the Denver Broncos are asking a federal court to reject a player’s lawsuit alleging discrimination over penalties he incurred due to positive THC tests from his prescribed use of a synthetic cannabinoid.

In a joint motion to dismiss filed with the U.S. District Court for the District of Colorado last week, the league and team defended their marijuana policy for players, affirming it’s their view that use of cannabis can lead to on-field injuries, poor job performance and “alienation of the fans.” And they challenged the discrimination claims from Randy Gregory, who played for the Broncos before transferring to the San Francisco 49ers.

Gregory filed his suit in a state district court last month, arguing that NFL and the Broncos violated the Colorado Anti-Discrimination Act (CADA) by penalizing him for using the Food and Drug Administration- (FDA) approved cannabis medication dronabinol to treat anxiety, post-traumatic stress disorder (PTSD) and pain. The case was moved to the federal court earlier this month.

The defendants responded by arguing that those claims are “completely preempted” by the federal Labor Management Relations Act (LMRA), and they said U.S. Supreme Court and federal circuit court precedent on collective bargaining agreements demonstrate that “Plaintiff’s claims under state law must be dismissed.”

The motion to dismiss also asserts that Gregory’s allegation that the NFL and Broncos violated Colorado’s anti-discrimination law falls flat because the statute doesn’t expressly protect workers from being penalized over marijuana use, regardless of whether its used for medical purposes in compliance with state law.

Keep reading

Cannabis Is More Effective In Treating Musculoskeletal Pain Than Traditional Medications Are, Patients Say In New Study

More than 1 in 5 patients who go to orthopedic surgeons with chronic musculoskeletal pain are using or have used some form of cannabis to manage their pain, according to a new study published this month. Of those, almost two thirds said they felt cannabis was very or somewhat effective, while more than 9 in 10 said it was at least slightly effective.

“More than half (57%) claimed cannabis to be more effective than other analgesic medications, and 40% reported decreasing their use of other analgesic medications since starting cannabis use,” the research found, adding that only 26 percent reported a doctor recommended cannabinoids to them to treat their musculoskeletal (MSK) pain.

Notably, among those who said they used cannabis to manage pain, the most commonly used cannabinoid was CBD (39 percent), followed by a hybrid of multiple cannabinoids (20 percent). Almost a quarter (23 percent) said they were unaware of their cannabis’s composition.

Further, among patients who were not cannabis users, roughly two thirds (65 percent) said they were interested in using marijuana to manage their pain but reported barriers to use such as “lack of knowledge regarding access, use and evidence, and stigma,” although stigma was, contrary to previous research, not a primary concern.

Keep reading